| Literature DB >> 32848591 |
Chang Li1,2, Zhiwei Zuo3, Daihong Liu2, Rui Jiang3, Yang Li2, Haitao Li2, Xuntao Yin4, Yuqi Lai5, Jian Wang2, Kunlin Xiong1.
Abstract
BACKGROUND: The precise physiopathological association between the courses of neurodegeneration and cognitive decline in type 2 diabetes mellitus (T2DM) remains unclear. This study sought to comprehensively investigate the distribution characteristics of gray matter atrophy in middle-aged T2DM patients with newly diagnosed mild cognitive impairment (MCI).Entities:
Keywords: atrophy; gray matter; mild cognitive impairment; structural covariance; type 2 diabetes mellitus
Year: 2020 PMID: 32848591 PMCID: PMC7432296 DOI: 10.3389/fnins.2020.00856
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Demographic features, biochemical measurements, and neuropsychological performance.
| Characteristic | HC ( | MCI ( | T2DM-MCI ( | T2DM ( | Diagnosis effect | |
| Age, years | 53.9 ± 1.2 | 56.6 ± 1.1 | 56.5 ± 1.2 | 54.8 ± 1.2 | 0.229a | |
| Sex, female : male | 15:13 | 20:8 | 17:11 | 18:10 | χ2 = 1.98 | 0.576b |
| Education, years | 12.3 ± 0.7 | 11.3 ± 0.6 | 11.0 ± 0.5 | 12.4 ± 0.6 | 0.372a | |
| Duration of T2DM | - | - | 8.2 ± 1.0 | 8.3 ± 1.3 | 0.965c | |
| BMI, kg/m2 | 23.5 ± 0.5 | 23.1 ± 0.4 | 24.8 ± 0.5 | 25.8 ± 1.2 | 0.035a* | |
| SBP, mm Hg | 127.4 ± 3.8 | 128.8 ± 3.2 | 131.4 ± 3.3 | 127.1 ± 2.8 | 0.648a | |
| DBP, mm Hg | 79.0 ± 1.7 | 78.4 ± 1.9 | 80.1 ± 1.9 | 78.8 ± 1.9 | 0.921d | |
| FPG, mmol/L | 5.5 ± 0.1 | 5.5 ± 0.1 | 10.4 ± 0.6 | 8.6 ± 0.6 | < 0.0001d * | |
| HbA1C (%) | 5.5 ± 0.1 | 5.6 ± 0.1 | 9.8 ± 0.6 | 8.8 ± 0.3 | < 0.0001a * | |
| Total cholesterol, mmol/L | 5.1 ± 0.2 | 5.4 ± 0.1 | 5.3 ± 0.2 | 4.8 ± 0.3 | 0.062a | |
| TG, mmol/L | 1.5 ± 0.1 | 1.9 ± 0.5 | 2.4 ± 0.4 | 2.6 ± 0.7 | 0.137a | |
| HDL cholesterol, mmol/L | 1.4 ± 0.1 | 1.5 ± 0.1 | 1.2 ± 0.1 | 1.1 ± 0.0 | < 0.0001d * | |
| LDL cholesterol, mmol/L | 3.1 ± 0.1 | 3.4 ± 0.1 | 3.4 ± 0.2 | 2.9 ± 0.1 | 0.018d* | |
| TMT-A | 48.1 ± 2.4 | 60.1 ± 4.2 | 64.6 ± 4.2 | 49.6 ± 4.0 | 0.005d* | |
| TMT-B | 60.1 ± 4.0 | 79.3 ± 4.9 | 99.8 ± 8.7 | 68.8 ± 5.8 | < 0.0001a* | |
| MoCA score | 27.7 ± 0.2 | 22.0 ± 0.5 | 22.1 ± 0.4 | 27.1 ± 0.2 | < 0.0001a * | |
| MMSE score | 28.5 ± 0.2 | 27.1 ± 0.3 | 27.8 ± 0.2 | 28.3 ± 0.2 | 0.003a * |
FIGURE 1Surface maps of significant differences in cortical volumes between healthy controls (HCs) and patients with mild cognitive impairment (MCI) (A), between HCs and patients with type 2 diabetes mellitus and MCI (T2DM-MCI) (B), between patients with MCI and patients with T2DM-MCI (C), and between patients with T2DM and patients with T2DM-MCI (D). Differences in cortical volume are presented on inflated cortical surfaces (clusterwise-corrected p-value < 0.05). Dark gray indicates gyri; light gray indicates sulci. The color bar represents t-values ranging from 2 to 5 (red to yellow). The numerals refer to the cluster numbers listed in Table 2.
Surface-based cluster summary of significant cortical changes.
| Cluster number | Size (mm2) | MNI coordinates of peak vertex | CWP | Anatomical location | |||
| 1 | 6.374 | 882.25 | −54.0 | 17.2 | 17.7 | 0.0002 | L pars opercularis |
| 2 | 5.653 | 624.73 | −25.5 | −1.2 | −29.5 | 0.0042 | L entorhinal cortex |
| 3 | 4.741 | 681.83 | −39.1 | −86.9 | −8.8 | 0.0018 | L lateral occipital cortex |
| 4 | 3.663 | 571.54 | −17.6 | −79.4 | 31.4 | 0.0078 | L superior parietal cortex |
| 5 | 5.413 | 561.52 | −11.0 | −58.3 | 12.8 | 0.0086 | L precuneus |
| 6 | 3.714 | 591.94 | 44.8 | 6.7 | 7.5 | 0.0070 | R precentral cortex |
| 7 | 3.843 | 613.67 | −43.2 | 37.7 | −14.0 | 0.0048 | L pars orbitalis |
| 8 | 8.061 | 562.66 | −43.9 | −22.4 | 21.1 | 0.0086 | L supramarginal gyrus |
| 9 | 4.728 | 732.01 | −39.2 | −86.9 | −7.5 | 0.0010 | L lateral occipital cortex |
| 10 | 4.104 | 687.45 | −10.1 | −58.1 | 11.4 | 0.0016 | L precuneus |
| 11 | 3.588 | 510.02 | 20.8 | −63.1 | 45.2 | 0.0195 | R superior parietal cortex |
| 12 | 3.758 | 523.84 | 53.8 | −21.4 | 19.5 | 0.0167 | R supramarginal gyrus |
| 13 | 4.241 | 1023.73 | 58.3 | −34.3 | −8.6 | 0.0002 | R middle temporal cortex |
| 14 | 4.093 | 846.49 | 41.0 | −13.7 | −12.0 | 0.0004 | R superior temporal cortex |
| 15 | 4.493 | 458.40 | 14.9 | −53.9 | 8.6 | 0.0402 | R isthmus cingulate cortex |
| 16 | 2.694 | 722.45 | 5.3 | −81.9 | 21.9 | 0.0014 | R cuneus |
| 17 | 4.634 | 485.16 | −33.2 | 48.8 | 8.7 | 0.0235 | L rostral middle frontal cortex |
| 18 | 4.751 | 922.47 | −42.1 | 27.4 | −14.3 | 0.0002 | L lateral orbitofrontal cortex |
| 19 | 5.112 | 1364.60 | −45.8 | −13.7 | 27.9 | 0.0002 | L post-central cortex |
| 20 | 4.467 | 722.46 | −54.2 | −32.1 | −25.8 | 0.0012 | L inferior temporal cortex |
| 21 | 5.728 | 482.85 | −41.8 | −45.5 | −15.0 | 0.0247 | L fusiform cortex |
| 22 | 4.206 | 979.14 | −6.1 | −68.6 | 43.7 | 0.0002 | L precuneus |
| 23 | 10.659 | 1088.50 | −15.0 | 31.6 | −22.0 | 0.0002 | L lateral orbitofrontal cortex |
| 24 | 4.705 | 1463.05 | 48.1 | −44.4 | 37.2 | 0.0002 | R supramarginal gyrus |
| 25 | 4.374 | 502.35 | 44.4 | −37.9 | −1.0 | 0.0213 | R banks of the superior temporal sulcus |
| 26 | 4.861 | 718.75 | 58.2 | −26.7 | −27.9 | 0.0014 | R inferior temporal cortex |
| 27 | 7.946 | 1157.67 | 5.3 | 32.8 | −24.0 | 0.0002 | R medial orbitofrontal cortex |
| 28 | 5.721 | 564.98 | 29.4 | −68.2 | −8.8 | 0.0108 | R fusiform cortex |
| 29 | 4.243 | 687.61 | −24.7 | 37.3 | −9.3 | 0.0016 | L lateral orbitofrontal cortex |
| 30 | 3.240 | 487.47 | −22.5 | 54.5 | 18.3 | 0.0225 | L rostral middle frontal cortex |
| 31 | 4.340 | 479.08 | 12.2 | −68.9 | 54.9 | 0.0306 | R superior parietal cortex |
| 32 | 3.663 | 483.89 | 37.0 | 40.5 | −9.1 | 0.0284 | R pars orbitalis |
FIGURE 2Significant differences in subcortical volume (A) and volume of the hippocampal subfields (B) among the HCs, patients with MCI, patients with type 2 diabetes mellitus and mild cognitive impairment (T2DM-MCI) and patients with type 2 diabetes mellitus (T2DM). *Bonferroni-corrected p-value < 0.05. **Bonferroni-corrected p-value < 0.001. The error bars indicate standard errors. HT, hippocampal tail; CA, cornu ammonis; HF, hippocampal fissure; ML, molecular layer; DG, granule cell layer of dentate gyrus; HATA, hippocampus-amygdala-transition-area.
FIGURE 3Network-style maps of significant differences in structural covariance within the default mode network between the HCs and patients with MCI (A), between the HCs and patients with type 2 diabetes mellitus and MCI (T2DM-MCI) (B), and between the MCI and T2DM-MCI groups (C). Differences in correlation coefficients for gray matter volume are presented on a standard translucent brain. Bonferroni-corrected p-value < 0.05.
FIGURE 4Partial correlation analysis results. CA, cornu ammonis; DG, granule cell layer of dentate gyrus; ML, molecular layer; TMT, Trail-Making Test; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination. Significant p-value < 0.01.